Patent 101 Workshop for Entrepreneurs and Start-Ups, HKSTP

2023年3月10日

Last Friday (10/3), our Vice President Jennifer Che met with Grace S N Lau of the Institute for Translational Research of HKSTP and the HKSTP community to discuss the fundamentals of IP and how “common” early-stage business/R&D activities can hurt your IP.

我們過去活動

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

2025年6月11日

Insights from HKSTP Market Discovery - BIO Connect

2025年5月28日

HKMHDIA Medical Fair Forum

2025年5月27日

Celebrating Innovation at the Asia Summit for Global Health

2025年5月26日

Recommended Insights

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

2021年10月19日

The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日

This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

China Releases Draft Examination Guidelines for the new Patent Law

2020年12月4日

The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日

Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]